# Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment

> **NCT05170438** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 51 (actual)

## Conditions studied

- Advanced Biliary Tract Cancer

## Interventions

- **DRUG:** Lenvatinib Pill,Paclitaxel

## Key facts

- **NCT ID:** NCT05170438
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05170438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05170438, "Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05170438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*